MicroRNA 106b-5p (miR-106b-5p)

MicroRNA 106b-5p (hsa-miR-106b-5p) is a mature, small non-coding RNA molecule that functions as a post-transcriptional regulator of gene expression by binding to the 3' untranslated regions (UTRs) of target messenger RNAs (PubMed, miRBase). It is a member of the miR-106b-25 cluster and is frequently overexpressed in various cancers, including breast, prostate, and lung cancer, where it acts as an oncomiR by silencing tumor suppressor genes such as PTEN, SMAD7, and BTG3 (NIH, MDPI). This silencing promotes oncogenic processes such as cell proliferation, migration, invasion, and resistance to chemotherapy drugs like cisplatin and gemcitabine (PubMed, NIH). Beyond its role in oncology, miR-106b-5p is implicated in the pathogenesis of Alzheimer's disease and is being investigated as a non-invasive biomarker in liquid biopsies (NIH, JensenLab). Therapeutic strategies focus on the use of antisense oligonucleotides, or antagomirs, to inhibit the miRNA's activity and restore the expression of its target genes (MedChemExpress, NIH). The development of these therapies faces challenges such as ensuring stable delivery to target tissues and minimizing off-target effects on other gene networks (NIH, JensenLab). Overall, miR-106b-5p represents a significant focal point for both diagnostic innovation and targeted cancer therapy (PubMed, NIH).

Other names

miR-106b-5phsa-miR-106bMIR106BMIRN106BMIMAT0000680

Antagomirs and miRNA inhibitors bind to the mature miRNA sequence through complementary base pairing, preventing the miRNA from interacting with its target mRNAs and thereby restoring the translation of tumor suppressor genes (MedChemExpress, NIH).